Lv6
2340 积分 2022-02-16 加入
Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF (V600E) mutation-positive metastatic non-small cell lung cancer
29天前
已完结
A phase II study of encorafenib + binimetinib combination in Chinese patients with BRAF V600E mutated metastatic non-small cell lung cancer
29天前
已完结
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer
1个月前
已完结
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer
1个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1个月前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
